| 查看: 1862 | 回复: 5 | |||
[交流]
【讨论】非索非那定的市场情况
|
|
求：非索非那定的 一、产品研发背景 1. 原研厂家 2. 研发时间与研究立意 3.国外的上市与销售情况 二、与现有竞争产品的比较 三、国内市场情况 1.批文数量及厂家（含规格） 2. 历史销售情况及分析 3.国内主要生产厂家的销售情况 |
回复此楼» 猜你喜欢
磺胺二甲嘧啶杂质
已经有0人回复
-
卡博替尼杂质
已经有0人回复
-
药理学论文润色/翻译怎么收费?
已经有218人回复
-
阿西替尼杂质
已经有0人回复
-
盐酸贝西沙星
已经有0人回复
-
姜黄烯杂质
已经有0人回复
-
克立硼罗
已经有0人回复
-
米拉贝隆
已经有0人回复
-
SPME-GC-O-MS
已经有0人回复
-
使用MolAICal生成小分子CHARMM力场拓扑和参数文件
已经有0人回复
» 本主题相关价值贴推荐，对您同样有帮助:
- 现在国内有那几家在生产毒莠定？市场情况如何？
已经有4人回复
» 抢金币啦！回帖就可以得到:
-
【26年9月入学】中国石油大学（北京） 化学工程专业招2026级学术博士1名
+1/273
-
山东征女友，坐标济南
+1/166
-
未婚80后理工男_征珠三角如深圳或周边温柔贤惠孝勤女
+2/162
-
寻找做兼职的医学同学，长期的（长三角：血管介入医疗器械方面兼职）
+2/140
-
华南师范大学海洋环境科学课题组招聘青年英才和博士后
+2/106
-
温州医科大学沈建良课题组招聘2026级博士生
+1/100
-
香港科技大学（广州）章勇课题组招收钙钛矿太阳能电池方向博士生、博士后
+1/97
-
【专业EPR】：自由基(超氧、羟基、单线态氧)，空位缺陷；定量计算，VX: 761711562。
+1/85
-
广东工业大学自动化学院国家特聘专家苏春翌教授招收2026年博士后及硕博研究生（推免）
+1/77
-
中山大学柔性电子学院柏效鹏课题组诚聘博士后
+2/34
-
【通知】北京信息科技大学仪器科学与光电工程学院招收调剂生（2026），快来报名吧！
+1/30
-
【通知】北京信息科技大学仪器科学与光电工程学院招收博士研究生（2026），还有名额！
+1/28
-
“双一流”南京邮电大学--海优团队--招收2026博士生1-2名（6月15日前有效）
+1/10
-
地大武汉（211）招生光刻胶半导体方向博士生
+1/9
-
温州医科大学王毅课题组招聘2026级博士生
+1/9
-
电子科技大学材料学院SFT创新中心招收准备考研和读博的科研助理 理工医交叉方向
+1/4
-
电子科技大学材料学院SFT创新中心招收准备考硕和读博的科研助理 理工医交叉方向
+1/2
-
上海大学微电子学院杨军教授团队招聘带编专任教师
+1/2
-
储能与电子材料课题组 招收硕士 or 博士研究生——以色列理工-GTIIT联培
+1/1
-
深圳大学材料学院“智能分子材料团队”招聘博士后（连续流微反应器方向优先）
+1/1
2楼2011-03-18 12:51:27
★ ★ ★
warlen(金币+1): 谢谢参与 2011-03-18 15:54:09
空城若虚(金币+40): 非常感谢！ 2011-03-18 20:13:20
caoyuan521(金币+2): 谢谢参与！ 2011-03-18 21:04:15
warlen(金币+1): 谢谢参与 2011-03-18 15:54:09
空城若虚(金币+40): 非常感谢！ 2011-03-18 20:13:20
caoyuan521(金币+2): 谢谢参与！ 2011-03-18 21:04:15
|
Fexofenadine hydrochloride Cas number: 153439-40-8, 138452-21-8 - General description: Fexofenadine (trade names Allegra, Telfast, Fastofen, Tilfur, Vifas, Telfexo, Allerfexo) is an antihistamine drug used in the treatment of hayfever and similar allergy symptoms. It was developed as a successor of and alternative to terfenadine (trade names include Triludan and Seldane), an antihistamine which caused QT interval prolongation, potentially leading to cardiac arrhythmia. It has been described as both second-generation[3] and third-generation antihistamine. The older antihistaminic agent terfenadine was found to metabolize into the related carboxylic acid, fexofenadine. Fexofenadine was found to retain all of the biological activity of its parent while giving fewer adverse reactions in patients, so terfenadine was replaced in the market by its metabolite.[8] Fexofenadine was originally synthesized in 1993 by Massachusetts-based biotechnology company Sepracor, which then sold the development rights to Hoechst Marion Roussel (now part of Sanofi-Aventis), and was later approved by the Food and Drug Administration (FDA) in 1996. AMRI holds the patents to the intermediates and production of fexofenadine HCl along with Roussel. Since that time, it has achieved blockbuster drug status with global sales of $1.87B USD in 2004 (with $1.49B USD coming from the United States). AMRI received royalty payments from Aventis that enabled the growth of AMRI. On January 25, 2011, the FDA approved over-the-counter sales of fexofenadine in the United States, with Sanofi-Aventis' version expected to become available on March 4, 2011. I. Originator:Aventis Pharma, Sepracor; Marketer: ViroPharma; Reference patent: JP 1996502022; WO 9321156; II. Main Competitors in U.S: N021963 Yes FEXOFENADINE HYDROCHLORIDE SUSPENSION; ORAL 30MG/5ML ALLEGRA SANOFI AVENTIS US -------------------------------------------------------------------------------- A076191 AB No FEXOFENADINE HYDROCHLORIDE TABLET; ORAL 180MG FEXOFENADINE HYDROCHLORIDE BARR -------------------------------------------------------------------------------- A076191 AB No FEXOFENADINE HYDROCHLORIDE TABLET; ORAL 30MG FEXOFENADINE HYDROCHLORIDE BARR -------------------------------------------------------------------------------- A076191 AB No FEXOFENADINE HYDROCHLORIDE TABLET; ORAL 60MG FEXOFENADINE HYDROCHLORIDE BARR -------------------------------------------------------------------------------- A076502 AB No FEXOFENADINE HYDROCHLORIDE TABLET; ORAL 180MG FEXOFENADINE HYDROCHLORIDE DR REDDYS LABS LTD -------------------------------------------------------------------------------- A076502 AB No FEXOFENADINE HYDROCHLORIDE TABLET; ORAL 30MG FEXOFENADINE HYDROCHLORIDE DR REDDYS LABS LTD -------------------------------------------------------------------------------- A076502 AB No FEXOFENADINE HYDROCHLORIDE TABLET; ORAL 60MG FEXOFENADINE HYDROCHLORIDE DR REDDYS LABS LTD -------------------------------------------------------------------------------- A077081 AB No FEXOFENADINE HYDROCHLORIDE TABLET; ORAL 180MG FEXOFENADINE HYDROCHLORIDE MYLAN -------------------------------------------------------------------------------- A077081 AB No FEXOFENADINE HYDROCHLORIDE TABLET; ORAL 30MG FEXOFENADINE HYDROCHLORIDE MYLAN -------------------------------------------------------------------------------- A077081 AB No FEXOFENADINE HYDROCHLORIDE TABLET; ORAL 60MG FEXOFENADINE HYDROCHLORIDE MYLAN -------------------------------------------------------------------------------- A076447 AB No FEXOFENADINE HYDROCHLORIDE TABLET; ORAL 180MG FEXOFENADINE HYDROCHLORIDE TEVA -------------------------------------------------------------------------------- A076447 AB No FEXOFENADINE HYDROCHLORIDE TABLET; ORAL 30MG FEXOFENADINE HYDROCHLORIDE TEVA -------------------------------------------------------------------------------- A076447 AB No FEXOFENADINE HYDROCHLORIDE TABLET; ORAL 60MG FEXOFENADINE HYDROCHLORIDE TEVA -------------------------------------------------------------------------------- A076236 AB No FEXOFENADINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE TABLET, EXTENDED RELEASE; ORAL 60MG;120MG FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE BARR -------------------------------------------------------------------------------- A079043 No FEXOFENADINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE TABLET, EXTENDED RELEASE; ORAL 180MG;240MG FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE DR REDDYS LABS LTD -------------------------------------------------------------------------------- A076298 AB No FEXOFENADINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE TABLET, EXTENDED RELEASE; ORAL 60MG;120MG FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE IMPAX PHARMS III. China Domestic Market I suggest you to look through the SFDA website to get related informations. It is not difficult. IV. The market information is not easy to acquire. I suggest you to purchase IMS data or BMI data. |
3楼2011-03-18 13:36:14
4楼2011-03-18 20:10:17
我主要是为了赚BB5楼2011-03-18 21:35:10
6楼2011-03-29 08:47:19